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Synthesis of orthogonally protected azalanthionines (lanazanines) by sequential 
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Abstract: 
Orthogonally protected azalanthionines (lanazanines, 4-azadiaminopimelic acids or β-
aminoalaninoalanines) have been synthesised in good yields by the ring-opening of N-
protected aziridine 2-carboxylates with suitably protected diaminopropanoic acids 
(DAPs). The required DAPs were also synthesised by ring-opening of N-protected 
aziridine 2-carboxylates with para-methoxybenzylamine. 
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Many peptides contain a disulfide bridge, formed by the oxidative linking of two 
cysteine residues, but in lanthionine-containing peptides (lanthipeptides)1 this is a 
bridge with a single sulfur atom (thioether). An azalanthionine (lanazanine) is thus the 
N-linked analogue of this more common lanthionine moiety. There have been very 
few reports of the synthesis, or use, of azalanthionines (Figure 1). Pleixats described 
the isolation of an azalanthionine, as a by-product, from the FeCl3-catalysed addition 
of an amine to a didehydroalanine (Dha),2 while Paulus has reported the observation 
of azalanthionines, as intermediates in the formation of imidazolines, from the non-
selective addition of ammonia to a Dha moiety.3 A stereoselective synthesis of 
another protected azalanthionine analogue, though not orthogonally protected, was 
reported by Kim via the ring-opening of cyclic sulfamidates with benzylamines, en 
route to the synthesis of chiral peraza-macrocycles.4 The lantibiotics (lanthionine-
containing antibiotics) are a subset of antimicrobial peptides which are active against 
a wide range of bacterial species, and contain a number of unusual amino acid 
residues in their structures.5 These residues are formed by post-translational 
modifications and include lanthionine, β-methyllanthionine, Dha and 
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didehydrobutyrine (Dhb), amongst others. Vederas has recently shown that it is 
possible to replace the thioether linker in lanthionines with either a hydrocarbon or 
ether linker (oxalanthionine, Figure 1), while maintaining biological activity, when 
they are incorporated into peptides.6 The goal of our studies was to extend the range 
of possible thioether replacements in lanthionines by preparing analogues containing 
an amine linker. The efficient incorporation of an amine-linked analogue into peptides 
would first require the preparation of a suitably orthogonally protected azalanthionine 
(lanazanine, 4-azadiaminopimelic acid or β-aminoalaninoalanine) for subsequent use 
in solid-phase peptide synthesis. Tabor has reported a multi-step synthetic route for 
orthogonally protected lysinoalanines, which are chain-extended analogues of the 
azalanthionines.7 
 
It was envisaged that the preparation of the required orthogonally protected 
azalanthionines would be possible from the ring-opening of suitably protected 
aziridine 2-carboxylates with protected DAPs (Scheme 1). The required protected 
aziridine 2-carboxylates were prepared from serine derivatives by literature methods. 
The N-trityl precursor 1 was prepared in two steps from L-serine methyl ester, 
following the method of Zwanenburg.8 Following removal of the trityl group, the 
aziridine nitrogen was protected separately with the tosyl or p-nosyl group (para-
nitrobenzenesulfonyl) to give the aziridines 2 and 3. Synthesis of the desired 
azalanthionines would therefore require the ring-opening of these aziridine 2-
carboxylates with a suitably protected DAP. This involved thermal ring-opening of 
the previously prepared aziridine 2-carboxylates with p-methoxybenzylamine in 
acetonitrile at 80 oC for 24 h, following the method of Kim.9 To avoid double addition 
two molar equivalents of the benzylamine was used. Using aziridine 2, attack at the 
less hindered β-position of the aziridine gave an isolated yield of only 32% of the 
desired DAP 4, along with 41% of the regioisomeric DAP 5, formed by attack of the 
benzylamine at the α-position of the aziridine 2. When the same reaction was 
undertaken at room temperature, for 24 h, there was a reversal in the selectivity with 
the desired DAP 4 being obtained in a 70% isolated yield, with only a 23% yield of 
the regioisomer 5. The regioselectivity at elevated temperatures was not unexpected, 
but the fact that there was still a significant amount of reaction at the more hindered 
α-position, even at room temperature, was somewhat of a surprise. Literature reports 
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of the reaction of activated aziridines at room temperature usually show that 
nucleophilic attack occurs at the less hindered β-position, unless the α-position is 
allylic or benzylic.10 
 
With the required DAP in hand the first synthesis of an azalanthionine was achieved 
by reaction of 4 with the N-nosyl aziridine 3. When the reaction was performed at 
room temperature, no product formed due to the extra steric hindrance of the 
secondary p-methoxybenzyl substituted amine of the DAP 4. However, heating to 80 
oC gave the azalanthionine 6 in a 51% yield, as the sole product, with no evidence of 
attack at the α-position being observed. 
 
Previously, we showed that protected DAPs could also be prepared from serine 
derivatives by the Mitsunobu reaction with sulfonamides, but these syntheses were 
somewhat difficult to reproduce with large variations in the isolated yields being 
obtained.11 However, the fully protected DAP 8 was prepared from serine derivative 7 
using this method, in a 63% yield (Scheme 2). Removal of the p-Ns group of 8 was 
achieved in an 80% yield, using thiophenol, giving the secondary PMB-protected 
DAP 9. It was noted that attempts to prepare 9 directly by ring-opening of N-alloc 
aziridine 2-allyl ester with p-methoxybenzylamine were unsuccessful. Surprisingly, 
no thermal reaction of 9 with aziridine 2 was observed, but when BF3.OEt2 was used 
as a Lewis acid catalyst, in CH2Cl2 at reflux temperature, the azalanthionine 10 was 
obtained in a poor yield of 30%, even after 24 hours.  
 
Neither of the prepared azalanthionines (6 and 10) were orthogonally protected which 
would be advantageous for their use in peptide synthesis. Previously, Vederas 
successfully used the para-nitrobenzyloxycarbonyl (p-Nz) protecting group in the 
synthesis of orthogonally protected oxalanthionine analogues.6 As the route to the 
required DAPs, using ring-opening of aziridine 2-carboxylates with PMB-NH2, was 
more efficient than the Mitsunobu reaction route, the orthogonally protected DAP 13 
(Scheme 3), containing the p-Nz group, was prepared from the p-Nz protected 
aziridine 12.12 In this case when the reaction was performed at room temperature the 
product from attack at the β-position was the sole product obtained, in a 66% yield. 
There was no evidence for the product from attack at the α-position, which, in this 
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case, is in agreement with the literature reports of similar types of reactions.10 
However, the outcome was quite different to that found for the synthesis of the Dap 4 
(using N-tosyl aziridine methyl ester 2, Scheme 1), where attack at both the α- and β-
position was observed at room temperature. Currently, we are expanding the study of 
these reactions with different combinations of protecting groups on the aziridine 2-
carboxylates, to see how the choice of the activating protecting groups influences both 
the regioselectivity and the overall success, or otherwise, of the ring-opening 
reactions. The results of these studies will be reported in due course. 
 
With the DAP 13 in hand, subsequent reaction with aziridine 2, in acetonitrile at 
reflux temperature for 24 h, gave the fully orthogonally protected azalanthionine 14 in 
a 38% yield. The azalanthionine 15, which contained the more peptide-synthesis-
friendly p-Ns protecting group in place of the N-tosyl group, was prepared in a similar 
manner using aziridine 3, but in a diminished yield of 32%. Since both partners used 
for the azalanthionine synthesis were derived from L-serine, the stereochemistry of the 
two stereocentres of the product was not analogous to that found in natural 
lanthionines. Therefore, the synthesis was repeated with the enantiomer of aziridine 3, 
which was prepared from D-serine. This gave the fully orthogonally protected 
diastereoisomeric azalanthionine 16 with the correct stereochemistry, in a yield of 
38%. Finally, it was found that the azalanthionines prepared in this study were prone 
to decomposition during their purification and characterisation, when stored at 
ambient temperature, both as pure samples and in solutions of organic solvents, 
particularly solvents used for column chromatography and NMR analysis. For 
example, azalanthionine 6 was the most stable azalanthionine synthesised but was still 
fully decomposed after two weeks when stored at ambient temperature, under a 
nitrogen atmosphere, with multiple products being observed by chromatographic and 
NMR analyses. It seems that the same very strongly electron-withdrawing aziridine 
N-substituents required in order to activate the aziridines sufficiently for nucleophilic 
attack are also the substituents responsible for the observed decomposition. However, 
when compound 6 was stored at -20 oC it showed an increase in stability with the 
shelf-life increasing to greater than one month, instead of less than two weeks, as seen 
by HPLC and NMR analyses. It is likely that when the azalanthionines are 
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incorporated into peptide structures, in the future, they will be more stable due to the 
absence of these highly electron-withdrawing substituents. 
 
In conclusion, we have demonstrated the first synthesis of orthogonally protected 
azalanthionines, amine-linked analogues of the biologically important lanthionines. 
Currently, this chemistry is being extended to the synthesis of the corresponding 
orthogonally protected β-methylazalanthionines as analogues of the β-
methyllanthionines found in the ring structures of many important lantibiotics.5 The 
results of these studies will be reported in due course. 
 
Typical procedure for azalanthionine synthesis, exemplified by the synthesis of 6. N-p-
Nosyl aziridine methyl ester 3 (0.07 g, 0.25 mmol) was dissolved in MeCN (5 ml) 
before adding DAP 4 (0.2 g, 0.5 mmol, 2 eq.) after which the solution was stirred at 
reflux temperature for 24 h, before removing the solvent in vacuo. The resulting oil 
was dissolved in EtOAc (20 ml), washed with brine (2 x 20 ml) and dried over 
anhydrous MgSO4, before removing the solvent in vacuo. The crude residue was 
purified by preparative TLC on silica gel (petroleum ether:EtOAc 4:1) to yield 6 as a 
pale yellow oil (0.09 g, 51%). Rf:  0.37 petroleum ether: EtOAc (1:1). [α]D20 = +32.96 
(c = 1 in CHCl3). 1H NMR (CDCl3) δ ppm; 8.34 (d, 2H, J = 8.7 Hz), 8.06 (d, 2H, J = 
8.7 Hz), 7.73 (d, 2H, J = 8.4 Hz), 7.28 (d, 2H, J = 8.3 Hz), 7.13 (d, 2H, J = 8.5 Hz), 
6.82 (d, 2H, J = 8.5 Hz), 4.14 (s, 1H), 4.06 (s, 1H), 3.80 (s, 3H), 3.80 (d, 1H, J = 
12.9), 3.50 (d, 1H, J = 12.9 Hz), 3.46 (s, 3H), 3.41 (s, 3H), 3.02 (m, 3H), 2.76 (m, 
1H), 2.42 (s, 3H). 13C NMR (CDCl3) δ ppm; 171.1, 170.8, 159.1, 149.9, 146.1, 143.8, 
136.6, 130.8, 130.6, 129.6, 128.4, 127.2, 124.1, 113.8, 58.4, 56.7, 56.2, 55.2, 55.1, 
52.68, 52.63, 21.6. IR (thin film, NaCl) cm-1, 3356, 3089, 2982, 1744, 1732, 1532, 
1379, 1173, 1133. HRMS: ES+ for C29H34N4O11S2, expected [M+H] 679.1738, 
observed [M+H] 679.1748. 
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Figure 1. Structures of Lanthionine, Oxalanthionine and Azalanthionine 
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